Published in

Taylor and Francis Group, Leukemia & Lymphoma, 11(61), p. 2700-2707, 2020

DOI: 10.1080/10428194.2020.1775214

Links

Tools

Export citation

Search in Google Scholar

Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience

Journal article published in 2020 by Armon Azizi ORCID, Asiri Ediriwickrema, Ritika Dutta, Shyam A. Patel ORCID, William Shomali ORCID, Bruno Medeiros, David Iberri, Jason Gotlib, Gabriel Mannis, Peter Greenberg, Ravindra Majeti ORCID, Tian Zhang ORCID
Distributing this paper is prohibited by the publisher
Distributing this paper is prohibited by the publisher

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO